The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma

Lucio Tentori, Annalisa Susanna Dorio, Alessia Muzi, Pedro Miguel Lacal, Federica Ruffini, Pierluigi Navarra, Grazia Graziani

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Inhibitors of αv integrins have been developed as anti-angiogenic agents for cancer therapy and, among them, cyclic RGD-containing pentapeptides, such as cilengitide, are the most commonly used integrin antagonists. In this study, cilengitide was tested in combination with the methylating agent temozolomide (TMZ), a well-tolerated anticancer drug with favourable pharmacokinetic properties currently used for the therapy of metastatic melanoma. To this end, the influence of cilengitide and TMZ on malignant melanoma growth and endothelial cell proliferation were investigated, using in vitro and in vivo models. The results indicated that cilengitide and TMZ exerted synergistic antiproliferative effects against melanoma and endothelial cells in vitro and induced a statistically significant reduction of in vivo melanoma growth with respect to treatment with the methylating agent only. In conclusion, this study proposes the use of cilengitide in combination with TMZ for the treatment of metastatic melanoma, thereby opening novel perspectives for the use of integrin inhibitors to enhance the efficacy of chemotherapy.

Original languageEnglish
Pages (from-to)1039-1043
Number of pages5
JournalOncology Reports
Volume19
Issue number4
Publication statusPublished - Apr 2008

Fingerprint

temozolomide
Integrins
Melanoma
Endothelial Cells
Therapeutics
Growth
Pharmacokinetics
Cell Proliferation
Cilengitide
Drug Therapy

Keywords

  • Cilengitide
  • Integrin
  • Malignant melanoma
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tentori, L., Dorio, A. S., Muzi, A., Lacal, P. M., Ruffini, F., Navarra, P., & Graziani, G. (2008). The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncology Reports, 19(4), 1039-1043.

The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. / Tentori, Lucio; Dorio, Annalisa Susanna; Muzi, Alessia; Lacal, Pedro Miguel; Ruffini, Federica; Navarra, Pierluigi; Graziani, Grazia.

In: Oncology Reports, Vol. 19, No. 4, 04.2008, p. 1039-1043.

Research output: Contribution to journalArticle

Tentori, L, Dorio, AS, Muzi, A, Lacal, PM, Ruffini, F, Navarra, P & Graziani, G 2008, 'The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma', Oncology Reports, vol. 19, no. 4, pp. 1039-1043.
Tentori, Lucio ; Dorio, Annalisa Susanna ; Muzi, Alessia ; Lacal, Pedro Miguel ; Ruffini, Federica ; Navarra, Pierluigi ; Graziani, Grazia. / The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. In: Oncology Reports. 2008 ; Vol. 19, No. 4. pp. 1039-1043.
@article{ea624fa82cbc4f7b84a1b2b046c220f1,
title = "The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma",
abstract = "Inhibitors of αv integrins have been developed as anti-angiogenic agents for cancer therapy and, among them, cyclic RGD-containing pentapeptides, such as cilengitide, are the most commonly used integrin antagonists. In this study, cilengitide was tested in combination with the methylating agent temozolomide (TMZ), a well-tolerated anticancer drug with favourable pharmacokinetic properties currently used for the therapy of metastatic melanoma. To this end, the influence of cilengitide and TMZ on malignant melanoma growth and endothelial cell proliferation were investigated, using in vitro and in vivo models. The results indicated that cilengitide and TMZ exerted synergistic antiproliferative effects against melanoma and endothelial cells in vitro and induced a statistically significant reduction of in vivo melanoma growth with respect to treatment with the methylating agent only. In conclusion, this study proposes the use of cilengitide in combination with TMZ for the treatment of metastatic melanoma, thereby opening novel perspectives for the use of integrin inhibitors to enhance the efficacy of chemotherapy.",
keywords = "Cilengitide, Integrin, Malignant melanoma, Temozolomide",
author = "Lucio Tentori and Dorio, {Annalisa Susanna} and Alessia Muzi and Lacal, {Pedro Miguel} and Federica Ruffini and Pierluigi Navarra and Grazia Graziani",
year = "2008",
month = "4",
language = "English",
volume = "19",
pages = "1039--1043",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma

AU - Tentori, Lucio

AU - Dorio, Annalisa Susanna

AU - Muzi, Alessia

AU - Lacal, Pedro Miguel

AU - Ruffini, Federica

AU - Navarra, Pierluigi

AU - Graziani, Grazia

PY - 2008/4

Y1 - 2008/4

N2 - Inhibitors of αv integrins have been developed as anti-angiogenic agents for cancer therapy and, among them, cyclic RGD-containing pentapeptides, such as cilengitide, are the most commonly used integrin antagonists. In this study, cilengitide was tested in combination with the methylating agent temozolomide (TMZ), a well-tolerated anticancer drug with favourable pharmacokinetic properties currently used for the therapy of metastatic melanoma. To this end, the influence of cilengitide and TMZ on malignant melanoma growth and endothelial cell proliferation were investigated, using in vitro and in vivo models. The results indicated that cilengitide and TMZ exerted synergistic antiproliferative effects against melanoma and endothelial cells in vitro and induced a statistically significant reduction of in vivo melanoma growth with respect to treatment with the methylating agent only. In conclusion, this study proposes the use of cilengitide in combination with TMZ for the treatment of metastatic melanoma, thereby opening novel perspectives for the use of integrin inhibitors to enhance the efficacy of chemotherapy.

AB - Inhibitors of αv integrins have been developed as anti-angiogenic agents for cancer therapy and, among them, cyclic RGD-containing pentapeptides, such as cilengitide, are the most commonly used integrin antagonists. In this study, cilengitide was tested in combination with the methylating agent temozolomide (TMZ), a well-tolerated anticancer drug with favourable pharmacokinetic properties currently used for the therapy of metastatic melanoma. To this end, the influence of cilengitide and TMZ on malignant melanoma growth and endothelial cell proliferation were investigated, using in vitro and in vivo models. The results indicated that cilengitide and TMZ exerted synergistic antiproliferative effects against melanoma and endothelial cells in vitro and induced a statistically significant reduction of in vivo melanoma growth with respect to treatment with the methylating agent only. In conclusion, this study proposes the use of cilengitide in combination with TMZ for the treatment of metastatic melanoma, thereby opening novel perspectives for the use of integrin inhibitors to enhance the efficacy of chemotherapy.

KW - Cilengitide

KW - Integrin

KW - Malignant melanoma

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=43849087019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43849087019&partnerID=8YFLogxK

M3 - Article

C2 - 18357394

AN - SCOPUS:43849087019

VL - 19

SP - 1039

EP - 1043

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -